Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10502 in advanced solid tumors
NCT05740956Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-10502 in solid tumor, ovarian cancer, breast cancer and 3 more, sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum tolerated dose, Maximum applicable dose and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
HS-10502
03
Conditions
solid tumorovarian cancerbreast cancerpancreatic cancer (PC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05740956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740956.